Roche's big Chi­na play; Mer­ck bets on mR­NA, again; Blue­bird's gene ther­a­py takes off; Bet­ter PhI­II? At a frac­tion of the cost?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

There were days in the past few weeks where it’s felt re­al­ly qui­et on the news front — but then there are still enough im­por­tant de­vel­op­ments that we can’t bear to look away. See if you’ve missed any­thing this week. And if the End­points Week­ly has been help­ful for you, do spread the word.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.